AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06657235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Program
Description: Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. The participant will be monitored continuously while on the platform and up-to-date reports will be shared with the participant's relevant care providers every 30 days or as needed. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
Study NCT06620107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive high frequency oscillation ventilation
Description: cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2.
Study NCT06620107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied.
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Session
Description: Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second Session
Description: Training of peer mentors on communication techniques, interview methods and empathic approach.
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Third session
Description: Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fourth session
Description: Training of peer mentors on social motivation and leader-member interaction
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fifth Session
Description: Sharing postcasts with peer mentors on social motivation and leader-member interaction.
Study NCT06657443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sixth Session
Description: Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magrolimab
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT04958785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study NCT05900115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Ready Parent
Description: The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
Study NCT05900115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Program
Description: The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
Study NCT05590572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: (1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
Study NCT05590572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
Study NCT05590572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
Study NCT05590572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
Study NCT05590572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isophosphamide
Description: (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
Study NCT04892563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Nerve block with local anesthetic in the erector spinae plane
Study NCT04892563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Analgesia
Description: IV analgesia, typically Morphine/Opioid medications
Study NCT05850741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiokit
Description: The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
Study NCT06541444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK520
Description: The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
Study NCT05589142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time Restricted Eating
Description: Eating calories only during a specific feeding window.
Study NCT05589142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: Eating calories only during a specific feeding window.
Study NCT05706792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordic Sensi Chair
Description: The Nordic Sensi Chair is an electrically operated rocking chair with built-in MusiCure music composed by Niels Eje. It is equipped with an integrated audio system with music recording based on more than 15 years of research on the calming and mentally stimulating effect of sound. The Nordic Sensi Chair has three different programs: Relax for deep relaxation, Refresh for recovery and Comfort for gentle relaxation. A 5 kg fiber blanket increases the feeling of security and relaxation, while helping users to perceive their own body. In addition to musical programming, the Nordic Sensi Chair provides predefined tactile stimulation and rocking motion, for a relaxing multi-sensory experience. All settings can be easily customized at the touch of a button. For the purposes of this study, the NSC deep relaxation program (Relax Program) was used.
Study NCT05267626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-007
Description: Monoclonal Antibody Targeting IL-2
Study NCT05225597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracameral administration of epinephrine and carbachol during cataract surgery
Description: All surgeries were performed by the same surgeon using a similar technique, under topical anesthesia (0.05% proparacaine HCL), and with a 2.8 mm temporal clear corneal incision. After making the incision, 0.2 mL of preservative-free epinephrine (1:5000) was injected into the epinephrine group only. After complete hydrodissection, the nucleus was removed using the stop and chop technique. Phacoemulsification time (range: 30-60 s) was similar in all patients, while the phacoemulsification strength was set to 35%-40% for all operations. The cortex was aspirated. Before implanting a one-piece foldable hydrophobic acrylic intraocular lens (IOL) into the capsular bag, 1% sodium hyaluronate (ophthalmic viscosurgical device, Healon) was injected into the capsular bag. After removal of the viscoelastic material, only the carbachol group was given 0.5 ml of 0.01% carbachol solution intracamerally. Hydration with balanced salt solution was used to close the corneal incisions.
Study NCT05566860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positional Therapy
Description: After the a forementioned sleep endoscopy, if the patient has postural sleep apnea, he was treated with positional therapy for three months.
Study NCT05566860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Negative Pressure Therapy
Description: If the patient is effective with intraoral negative pressure therapy (iNAP), this therapy was used for three months.
Study NCT05267626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2
Study NCT05566860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Appliances
Description: If the patient is effective with oral appliances use, it was used be for three months.
Study NCT05566860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: If the interventions mentioned above are ineffective, or the patient does not want to try the above treatments, surgery is required. The surgical patients were divided into three groups according to their body weight. One group was overweight patients (BMI>32) who were treated with upper airway surgery and/or bariatric surgery, and/or postoperative diet education; the other group was overweight people with a BMI between 27 and 32, upper airway surgery and/or bariatric surgery, and/or postoperative diet education will be done; if the weight is normal with the BMI is less than 27, or those patients who are overweight but are not willing receive above mentioned weight loss treatment, upper airway surgery will be done.
Study NCT05566860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Muscle Strength Training
Description: If the tongue strength of the aforementioned patient is insufficient, it is recommended that the patient need to do tongue muscle strength training at the same time for three months. If the ambient temperature and humidity have an impact, we will recommend patients to control the ambient temperature and humidity and use the ECG patch to track the changes before and after three months.
Study NCT05267626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal Antibody Targeting PD-L1
Study NCT05473091 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: retrospective analysis
Study NCT05668520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system
Description: Consent Paperwork~* Nutritional assessment using MNA and MUST questionnaires~* 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference
Study NCT00512421 — intervention group
Intervention type: PROCEDURE
Intervention: computer-assisted surgery
Study NCT05375604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK-004
Description: ASO-STAT6 exosome administered Intravenously
Study NCT05832775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0029
Description: Megasphaera massiliensis MRx0029 (Treatment A) and Placebo
Study NCT05832775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRx0005
Description: Parabacteroides distasonis MRx0005 (Treatment B) and Placebo
Study NCT06237192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab for B-ALL, venetoclax for T-ALL
Description: MRD-associated based therapy for Ph-negative acute lymphoblastic leukemia
Study NCT06210932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social, Emotional, and Ethical Development (SEED) curriculum videos
Description: In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), A series of videos are developed based on the SEED curriculum, with specific themes for children in K2 and K3, each video last for approximately 10-12 minutes. They will watch three videos per week for a total of four weeks. The videos will be designed to promote social, emotional, and ethical development.
Study NCT05617495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + fMRI Neurofeedback
Description: Prior to neurofeedback, participants will receive 45 minutes of mindfulness training. Participants will then receive mindfulness-based fMRI neurofeedback targeting the default mode network and frontoparietal control network.
Study NCT05756192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
Study NCT04414917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twin block
Description: Dental local anesthetic administered to target the jaw 'closer' muscles, temporalis and masseter
Study NCT04414917 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iPill dispenser
Description: An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
Study NCT04414917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPill dispenser
Description: An active pill dispenser, regulated by patient's pain score entered on an iPill App installed on their smart phone (iPhone, Android) to dispense opioid (for pain corresponding to severe pain) or prescription strength ibuprofen and acetaminophen (for moderate pain), with over the counter solutions for mild pain recommended. This pill dispenser will be given to all patients, in both Twin block and Control groups, to regulate and monitor their pain experience-driven pain medication regimen. The pill dispenser will be packaged with pain medication (1 dispenser with vicodin, 1 with prescription ibuprofen, 1 with acetaminophen) that has been coencapsulated with ingestible event markers (IEMs, Proteus Discover).
Study NCT06281262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood collection
Description: The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations.
Study NCT05274750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depemokimab (GSK3511294)
Description: Depemokimab (GSK3511294) will be administered using a pre- filled syringe.
Study NCT05274750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study NCT05637255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1801
Description: 1 drop in the eligible eye
Study NCT06281262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Swab sample collection
Description: Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
Study NCT06583083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab with P-GEMOX Regimen
Description: Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Study NCT06583083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P-GEMOX Regimen
Description: Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Study NCT05715450 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Falciformopexy for Treatment Perforated Peptic Ulcer
Description: use the falciform ligament on perforated peptic ulcer
Study NCT05251441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breast Milk Fortifier supplements
Description: Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
Study NCT05251441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breast Milk Fortifier supplements
Description: Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
Study NCT05504213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352 combined with fulvestrant (Stage 1)
Description: Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study NCT05504213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352 combined with fulvestrant (Stage 2)
Description: Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study NCT05122325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device
Description: Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable).
Study NCT05122325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital vibration with Ferticare 2.0® vibrator
Description: Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
Study NCT05122325 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS® EMS NMS60 device_sham intervention
Description: Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment.